Jeffrey Smith

Company: Harvard Medical School

Job title: Instructor in Dermatology

Seminars:

Everyone Is Talking About JAK Inhibitors: Addressing Safety in Dermatology 10:30 am

As JAK inhibitors bring a level of efficacy unseen previously for Atopic Dermatitis, and Incyte’s Phase II in Hidradenitis Suppurativa reinforce the safety of the selective JAK1/ JAK2 inhibitor topical cream, is this enough to overcome the black box warning of 2021, or are dermatologists still wary of using this modality due to safety concerns?…Read more

day: Pre-Conference Workshops